Logo image of IMNM

IMMUNOME INC (IMNM) Stock Fundamental Analysis

NASDAQ:IMNM - Nasdaq - US45257U1088 - Common Stock - Currency: USD

8.49  +0.03 (+0.35%)

After market: 8.4799 -0.01 (-0.12%)

Fundamental Rating

3

Taking everything into account, IMNM scores 3 out of 10 in our fundamental rating. IMNM was compared to 560 industry peers in the Biotechnology industry. While IMNM has a great health rating, there are worries on its profitability. IMNM does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

IMNM had negative earnings in the past year.
IMNM had a negative operating cash flow in the past year.
In the past 5 years IMNM always reported negative net income.
IMNM had a negative operating cash flow in each of the past 5 years.
IMNM Yearly Net Income VS EBIT VS OCF VS FCFIMNM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

The Return On Assets of IMNM (-59.85%) is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -66.78%, IMNM is in line with its industry, outperforming 56.61% of the companies in the same industry.
Industry RankSector Rank
ROA -59.85%
ROE -66.78%
ROIC N/A
ROA(3y)-116.62%
ROA(5y)-86.52%
ROE(3y)-158.72%
ROE(5y)-114.11%
ROIC(3y)N/A
ROIC(5y)N/A
IMNM Yearly ROA, ROE, ROICIMNM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IMNM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMNM Yearly Profit, Operating, Gross MarginsIMNM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

More info and screens

8

2. Health

2.1 Basic Checks

IMNM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, IMNM has more shares outstanding
IMNM has more shares outstanding than it did 5 years ago.
IMNM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IMNM Yearly Shares OutstandingIMNM Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
IMNM Yearly Total Debt VS Total AssetsIMNM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

An Altman-Z score of 9.53 indicates that IMNM is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 9.53, IMNM belongs to the top of the industry, outperforming 88.04% of the companies in the same industry.
IMNM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 9.53
ROIC/WACCN/A
WACC9.55%
IMNM Yearly LT Debt VS Equity VS FCFIMNM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

2.3 Liquidity

A Current Ratio of 10.49 indicates that IMNM has no problem at all paying its short term obligations.
IMNM has a Current ratio of 10.49. This is in the better half of the industry: IMNM outperforms 79.64% of its industry peers.
IMNM has a Quick Ratio of 10.49. This indicates that IMNM is financially healthy and has no problem in meeting its short term obligations.
IMNM has a better Quick ratio (10.49) than 79.64% of its industry peers.
Industry RankSector Rank
Current Ratio 10.49
Quick Ratio 10.49
IMNM Yearly Current Assets VS Current LiabilitesIMNM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

3

3. Growth

3.1 Past

IMNM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 42.03%, which is quite impressive.
IMNM shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -13.77%.
EPS 1Y (TTM)42.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.28%
Revenue 1Y (TTM)-13.77%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%184.35%

3.2 Future

IMNM is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.56% yearly.
Based on estimates for the next years, IMNM will show a very strong growth in Revenue. The Revenue will grow by 100.97% on average per year.
EPS Next Y54.77%
EPS Next 2Y22.87%
EPS Next 3Y14.15%
EPS Next 5Y15.56%
Revenue Next Year-71.41%
Revenue Next 2Y35.5%
Revenue Next 3Y96.98%
Revenue Next 5Y100.97%

3.3 Evolution

IMNM Yearly Revenue VS EstimatesIMNM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
IMNM Yearly EPS VS EstimatesIMNM Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

IMNM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IMNM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMNM Price Earnings VS Forward Price EarningsIMNM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMNM Per share dataIMNM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

IMNM's earnings are expected to grow with 14.15% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.87%
EPS Next 3Y14.15%

More info and screens

0

5. Dividend

5.1 Amount

IMNM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IMMUNOME INC

NASDAQ:IMNM (5/23/2025, 8:25:11 PM)

After market: 8.4799 -0.01 (-0.12%)

8.49

+0.03 (+0.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)08-11 2025-08-11/amc
Inst Owners63.03%
Inst Owner Change42.78%
Ins Owners1.68%
Ins Owner Change8.57%
Market Cap738.71M
Analysts86.67
Price Target24.14 (184.33%)
Short Float %18.72%
Short Ratio11.53
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-45.82%
Min EPS beat(2)-116.8%
Max EPS beat(2)25.15%
EPS beat(4)1
Avg EPS beat(4)-37.69%
Min EPS beat(4)-116.8%
Max EPS beat(4)25.15%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)444.55%
Min Revenue beat(2)-14.94%
Max Revenue beat(2)904.04%
Revenue beat(4)2
Avg Revenue beat(4)228.43%
Min Revenue beat(4)-14.94%
Max Revenue beat(4)904.04%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-6.58%
PT rev (3m)-21.11%
EPS NQ rev (1m)22.84%
EPS NQ rev (3m)31.98%
EPS NY rev (1m)18.87%
EPS NY rev (3m)21.44%
Revenue NQ rev (1m)100%
Revenue NQ rev (3m)-26.12%
Revenue NY rev (1m)109.38%
Revenue NY rev (3m)-13.13%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 67.54
P/FCF N/A
P/OCF N/A
P/B 2.41
P/tB 2.41
EV/EBITDA N/A
EPS(TTM)-3.07
EYN/A
EPS(NY)-2.48
Fwd EYN/A
FCF(TTM)-2.06
FCFYN/A
OCF(TTM)-1.75
OCFYN/A
SpS0.13
BVpS3.53
TBVpS3.53
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -59.85%
ROE -66.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-116.62%
ROA(5y)-86.52%
ROE(3y)-158.72%
ROE(5y)-114.11%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1295.79%
Cap/Sales 239.42%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.49
Quick Ratio 10.49
Altman-Z 9.53
F-Score4
WACC9.55%
ROIC/WACCN/A
Cap/Depr(3y)1218.68%
Cap/Depr(5y)748.84%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.28%
EPS Next Y54.77%
EPS Next 2Y22.87%
EPS Next 3Y14.15%
EPS Next 5Y15.56%
Revenue 1Y (TTM)-13.77%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%184.35%
Revenue Next Year-71.41%
Revenue Next 2Y35.5%
Revenue Next 3Y96.98%
Revenue Next 5Y100.97%
EBIT growth 1Y-298.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year27.39%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-11945.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-8308.55%
OCF growth 3YN/A
OCF growth 5YN/A